These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 338136)

  • 1. Adriamycin plus alkylating agents in the treatment of metastatic breast cancer.
    Lokich JJ; Skarin AT; Mayer RJ; Henderson IC; Blum RH; Frei E
    Cancer; 1977 Dec; 40(6):2801-5. PubMed ID: 338136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.
    Bull JM; Tormey DC; Li SH; Carbone PP; Falkson G; Blom J; Perlin E; Simon R
    Cancer; 1978 May; 41(5):1649-57. PubMed ID: 348293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.
    Creech RH; Catalano RB; Harris DT; Engstrom PF; Grotzinger PJ
    Cancer; 1979 Jan; 43(1):51-9. PubMed ID: 367574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project.
    Smalley RV; Carpenter J; Bartolucci A; Vogel C; Krauss S
    Cancer; 1977 Aug; 40(2):625-32. PubMed ID: 329975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.
    De Lena M; Brambilla C; Morabito A; Bonadonna G
    Cancer; 1975 Apr; 35(4):1108-15. PubMed ID: 1116104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of metastatic breast cancer with adriamycin-cyclophosphamide induction followed by alternating combination therapy.
    Abeloff MD; Ettinger DS
    Cancer Treat Rep; 1977 Dec; 61(9):1685-9. PubMed ID: 340033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial.
    Muss HB; White DR; Richards F; Cooper MR; Stuart JJ; Jackson DV; Rhyne L; Spurr CL
    Cancer; 1978 Nov; 42(5):2141-8. PubMed ID: 363253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy for advanced breast cancer: two regimens containing adriamycin.
    Kennealey GT; Boston B; Mitchell MS; Knobf MK; Bobrow SN; Pezzimenti JF; Lawrence R; Bertino JR
    Cancer; 1978 Jul; 42(1):27-33. PubMed ID: 667798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinoma.
    Presant CA; Van Amburg A; Klahr C
    Cancer; 1977 Sep; 40(3):987-93. PubMed ID: 902247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adriamycin, cyclophosphamide, and 5-fluorouracil in the treatment of metastasizing breast cancer (author's transl)].
    Höffken K; Seeber S; Boecker WR; Schmidt CG
    Z Krebsforsch Klin Onkol Cancer Res Clin Oncol; 1976 Jun; 86(2):135-45. PubMed ID: 132786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adriamycin in combination for the treatment of breast cancer: a Southwest Oncology Group study.
    Tranum B; Hoogstraten B; Kennedy A; Vaughn CB; Samal B; Thigpen T; Rivkin S; Smith F; Palmer RL; Costanzi J; Tucker WG; Wilson H; Maloney TR
    Cancer; 1978 Jun; 41(6):2078-83. PubMed ID: 657081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone.
    Frederiksen PL; Joergensen ST; Roesdahl K; Thomsen J; Mouridsen HT
    Cancer Treat Rep; 1978 Mar; 62(3):449-50. PubMed ID: 348314
    [No Abstract]   [Full Text] [Related]  

  • 13. A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
    Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
    Chemioterapia; 1984 Aug; 3(4):216-9. PubMed ID: 6398121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy of metastatic carcinoma of the breast. A 4-drug regimen.
    Mattsson W; Gynning I; Tropé C; Astedt B
    Acta Radiol Ther Phys Biol; 1977 Apr; 16(2):97-108. PubMed ID: 301341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative trial of low-dose adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer.
    Lloyd RE; Jones SE; Salmon SE
    Cancer; 1979 Jan; 43(1):60-5. PubMed ID: 153787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response and survival in advanced breast cancer after two non-cross-resistant combinations.
    Brambilla C; De Lena M; Rossi A; Valagussa P; Bonadonna G
    Br Med J; 1976 Apr; 1(6013):801-4. PubMed ID: 1260337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First, second and third line chemotherapy programs in metastatic breast carcinoma.
    Rizel S; Sulkes A; Gez E; Brufman G; Biran S
    Isr J Med Sci; 1981; 17(9-10):946-53. PubMed ID: 6171542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185).
    Pandya KJ; Hu P; Osborne CK; Falkson G; Tormey DC;
    Am J Clin Oncol; 2007 Apr; 30(2):113-25. PubMed ID: 17414459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Encouraging results with cytostatic therapy in metastasizing breast cancer (author's transl)].
    Michlmayr G; Kratzer H; Denz H; Huber H
    Wien Klin Wochenschr; 1981 Mar; 93(6):205-7. PubMed ID: 7281697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
    Buzzoni R; Bonadonna G; Valagussa P; Zambetti M
    J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.